OTCMKTS:BNOEFBionomics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bionomics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.05 +0.00 (+4.44 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$0.05Now: $0.05▼$0.0550-Day Range$0.03MA: $0.05▼$0.0652-Week Range$0.01Now: $0.05▼$0.09Volume30,000 shsAverage Volume20,165 shsMarket Capitalization$25.60 millionP/E RatioN/ADividend YieldN/ABeta1.68 ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Bionomics. Previous Next 2.2 Community Rank Outperform VotesBionomics has received 46 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBionomics has received 59 “underperform” votes. (Add your “underperform” vote.)Community SentimentBionomics has received 56.19% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bionomics and other stocks. Vote “Outperform” if you believe BNOEF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BNOEF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBionomics does not currently pay a dividend.Dividend GrowthBionomics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bionomics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bionomics are expected to grow in the coming year, from ($0.03) to ($0.01) per share. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.57 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Noncommercial research organizations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BNOEF Previous Symbol CUSIPN/A CIKN/A WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares544,590,000Market Cap$25.60 million Next Earnings DateN/A OptionableNot Optionable OTC:BNOEF Rates by TradingView Receive BNOEF News and Ratings via Email Sign-up to receive the latest news and ratings for BNOEF and its competitors with MarketBeat's FREE daily newsletter. Bionomics (OTCMKTS:BNOEF) Frequently Asked Questions How has Bionomics' stock been impacted by COVID-19 (Coronavirus)? Bionomics' stock was trading at $0.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BNOEF shares have increased by 56.7% and is now trading at $0.0470. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Bionomics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bionomics. Has Bionomics been receiving favorable news coverage? News headlines about BNOEF stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bionomics earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Bionomics. Who are some of Bionomics' key competitors? Some companies that are related to Bionomics include Althea Group (AGH), Onconova Therapeutics (ONTX), Circassia Pharmaceuticals (CIR), Animalcare Group (ANCR), PAVmed (PAVM), WeedMD (WMD), Navidea Biopharmaceuticals (NAVB), Galmed Pharmaceuticals (GLMD), Patient Home Monitoring (PTQ), Windtree Therapeutics (WINT), Creative Realities (CRDF), Conatus Pharmaceuticals (CNAT), Endonovo Therapeutics (ENDV), Sanara MedTech (SMTI) and Spectral Medical (EDTXF). View all competitors. Who are Bionomics' key executives? Bionomics' management team includes the following people: Dr. Errol B. De Souza, Exec. Chairman (Age 66)Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS, Legal Counsel & Company Sec.Prof. Paul Rolan, Consultant Medical Officer of Clinical Neuroscience What is Bionomics' stock symbol? Bionomics trades on the OTCMKTS under the ticker symbol "BNOEF." How do I buy shares of Bionomics? Shares of BNOEF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Bionomics' stock price today? One share of BNOEF stock can currently be purchased for approximately $0.05. How big of a company is Bionomics? Bionomics has a market capitalization of $25.60 million. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
